利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

280 条记录 (耗时 0.021 秒)

    METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY
    1.
    发明公开
    METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY 审中-公开

    公开(公告)号：EP4012415A2

    公开(公告)日：2022-06-15

    申请号：EP21202223.0

    申请日：2016-12-02

    申请人： Juno Therapeutics, Inc. ,  Fred Hutchinson Cancer Research Center

    发明人： LI, He ,  GILBERT, Mark J. ,  MALONEY, David ,  RIDDELL, Stanley R. ,  TURTLE, Cameron J.

    IPC分类号： G01N33/68

    摘要： Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.

    DIAGNOSIS OF LYMPHOID MALIGNANCIES AND MINIMAL RESIDUAL DISEASE DETECTION
    4.
    发明公开
    DIAGNOSIS OF LYMPHOID MALIGNANCIES AND MINIMAL RESIDUAL DISEASE DETECTION 审中-公开

    公开(公告)号：EP3904536A1

    公开(公告)日：2021-11-03

    申请号：EP21163802.8

    申请日：2012-12-07

    申请人： Adaptive Biotechnologies Corporation ,  Fred Hutchinson Cancer Research Center

    发明人： SHERWOOD, Anna M. ,  ROBINS, Harlan S.

    IPC分类号： C12Q1/6886 ,  G16B30/00

    摘要： Methods are described for diagnosis of a lymphoid hematological malignancy in a subject prior to treatment, and for detecting minimal residual disease (MRD) in the subject after treatment for the malignancy, by high throughput quantitative sequencing (HTS) of multiple unique adaptive immune receptor (TCR or Ig) encoding DNA molecules that have been amplified from DNA isolated from blood samples or other lymphoid cell-containing samples. Amplification employs oligonucleotide primer sets designed to amplify CDR3-encoding sequences within substantially all possible human VDJ or VJ combinations. Disease-characteristic adaptive immune receptor clonotypes occur, prior to treatment, at a relative frequency of at least 15-30% of rearranged receptor CDR3-encoding gene regions. Following treatment, persistence of at least one such clonotype at a detectable frequency of at least 10 -6 or at least 10 -5 receptor CDR3-encoding regions indicates MRD. Improved quantitative embodiments are provided by inclusion of a template composition for amplification factor determination and related methods.